Glaring inconsistencies discovered in HeartWare trial PI interview: Northland


Northland Capital's Suraj Kalia says there are "glaring inconsistencies" between what HeartWare International (HTWR +0.8%) says about the final protocol for a destination therapy submission and what one of the principal investigators on the trial says.

Northland says Dr. Joseph Rogers expects to present data from the trial next year, but the company seems to say otherwise.

Rogers and the company also seem to disagree about whether or not data should be aggregated.

"How do you expect PI's to successfully 'defend' the trial, especially when they haven't been consulted about data analysis or presentation," Kalia asks.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs